新天药业(002873) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥208,755,879.11, a decrease of 16.24% compared to ¥249,216,213.05 in the same period last year[4] - Net profit attributable to shareholders was ¥25,092,336.81, down 18.74% from ¥30,879,340.57 year-on-year[4] - Basic earnings per share decreased to ¥0.1082, down 18.89% from ¥0.1334 in the same period last year[4] - Total operating revenue for Q1 2023 was CNY 208,755,879.11, a decrease of 16.3% compared to CNY 249,216,213.05 in Q1 2022[15] - Net profit for Q1 2023 was CNY 25,092,336.81, down 18.7% from CNY 30,879,340.57 in the same period last year[16] - Basic earnings per share decreased to CNY 0.1082 from CNY 0.1334, reflecting a decline of 18.5%[17] Cash Flow - The net cash flow from operating activities was -¥311,487.89, a decline of 108.43% compared to ¥3,695,741.81 in the previous year[4] - Cash flow from operating activities showed a net outflow of CNY 311,487.89, compared to a net inflow of CNY 3,695,741.81 in Q1 2022[17] - The net cash flow from financing activities increased by 36.75% to ¥50,602,908.34, primarily due to increased bank borrowings[7] - The net cash flow from financing activities was 50,602,908.34 CNY, compared to 37,005,120.20 CNY in the previous year[18] - The net cash flow from investment activities was -34,345,766.82 CNY, compared to a net cash flow of 31,179,154.70 CNY in the previous year[18] - The net increase in cash and cash equivalents was 15,945,653.63 CNY, down from 71,880,016.71 CNY year-over-year[18] - The ending balance of cash and cash equivalents was 116,613,200.61 CNY, compared to 144,358,114.14 CNY at the end of the previous year[18] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,902,558,635.90, an increase of 3.18% from ¥1,843,850,779.14 at the end of the previous year[4] - Total assets amounted to ¥1,902,558,635.90, up from ¥1,843,850,779.14, indicating an increase of about 3.2%[13] - Total liabilities increased to ¥747,021,674.97 from ¥714,648,981.41, a rise of approximately 4.5%[13] - The company reported a total of ¥1,263,779,120.13 in non-current assets, an increase from ¥1,229,856,973.52, reflecting a growth of approximately 2.7%[13] - The company’s total equity is reported at ¥1,155,536,960.93, showing a slight increase from the previous period[13] Shareholder Information - Total number of common shareholders at the end of the reporting period is 25,325[9] - The company has a total of 80,187,166 shares held by the largest shareholder, accounting for 34.57% of total shares[9] Expenses and Costs - Total operating costs decreased by 14.6% to CNY 183,519,448.53 from CNY 214,995,242.32 year-over-year[15] - The company reported a decrease in sales expenses to CNY 100,210,367.91 from CNY 121,925,070.24, reflecting cost management efforts[15] - Research and development expenses increased to CNY 3,990,027.82, up from CNY 3,589,480.60, indicating a focus on innovation[15] Tax and Government Subsidies - The company reported a significant increase in tax payable by 121.69%, reaching ¥13,154,202.38 due to higher VAT, property tax, and land use tax[7] - The company received government subsidies amounting to ¥1,116,830.60, which are closely related to its normal business operations[6] Other Information - The company recorded an asset impairment loss of -¥383,350.04, which is a 116.47% increase compared to -¥177,095.25 in the previous year[7] - The first quarter report was not audited[19] - The report was released by the board of directors on April 27, 2023[20] - The company did not report any significant new product launches or market expansions during this quarter[16] - There were no acquisitions or mergers reported in the current quarter[16]